(Q37219298)

19 August 2017

1 reference

title

Dementia of the Alzheimer type (English)

1 reference

19 August 2017

0 references

0 references

Jessica J Jalbert

1

1 reference

19 August 2017

Lori A Daiello

series ordinal

2

1 reference

19 August 2017

Kate L Lapane

series ordinal

3

1 reference

19 August 2017

publication date

16 July 2008

1 reference

19 August 2017

published in

Epidemiologic Reviews

1 reference

19 August 2017

volume

30

1 reference

19 August 2017

page(s)

15-34

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

19 August 2017

1 reference

The incidence of dementia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Alzheimer Disease in the US Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The spectrum of behavioral changes in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Prevalence and correlates of dysthymia and major depression among patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Prevalence of depression in Alzheimer's disease and validity of Research Diagnostic Criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Behavioral problems in dementia: a factor analysis of the neuropsychiatric inventory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Psychotic symptoms in Alzheimer disease: evidence for subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Proposals for re-evaluation of current autopsy criteria for the diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Amyloid beta protein (A beta) deposition in dementia with Lewy bodies: predominance of A beta 42(43) and paucity of A beta 40 compared with sporadic Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The Alzheimer family of diseases: many etiologies, one pathogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The importance of inflammatory mechanisms for the development of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Microglia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

In vivo neurotoxicity of beta-amyloid [beta(1-40)] and the beta(25-35) fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Neurotransmitter-related enzymes in senile dementia of the alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Pyramidal nerve cell loss in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Rate of cognitive decline and mortality in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Predictors of nursing home admission and/or death in incident Alzheimer's disease and other dementia cases compared to controls: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Delusions and hallucinations are associated with worse outcome in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Frontotemporal dementia progresses to death faster than Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Rates of progression in mild cognitive impairment and early Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Behavioral disturbance in dementia of the Alzheimer's type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The rate of decline in function in Alzheimer's disease and other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Incidence of and risk factors for hallucinations and delusions in patients with probable AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Neuropsychological correlates of apathy and depression in patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Symptoms of anxiety and depression in the course of cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Longitudinal cognitive decline in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Neuropsychological function in Alzheimer's disease. Pattern of impairment and rates of progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Decline of language among women and men with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

A personal view on the early history of the insulin-like growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Education and the course of cognitive decline in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Education and rates of cognitive decline in incident Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Hallucinations, delusions, and cognitive decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Depressive symptomatology and incident cognitive decline in an elderly community sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Alzheimer's disease and depression: neuropsychological impairment and progression of the illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Cerebral correlates of psychotic symptoms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Neuropathologic and neurochemical correlates of psychosis in primary dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The validity of 3 clinical diagnostic criteria for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Reliability and Validity of NINCDS-ADRDA Criteria for Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Diagnosing dementia: interrater reliability assessment and accuracy of the NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Population norms for the MMSE in the very old: estimates based on longitudinal data. Mini-Mental State Examination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The predictive value of dementia screening instruments in clinical populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Population-based norms for the Mini-Mental State Examination by age and educational level

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The Mini-Mental State Examination: A Comprehensive Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Diagnosing dementia: perspectives of primary care physicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Brief screening tests for the diagnosis of dementia: comparison with the mini-mental state exam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Establishing the limits of the Mini-Mental State. Examination of 'subtests'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Screening for dementia with the memory impairment screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Validation of a short Orientation-Memory-Concentration Test of cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Plasma biomarkers of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Plasma Abeta levels do not reflect brain Abeta levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Biomarkers of Alzheimer disease in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Medial temporal lobe atrophy on MRI in dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Magnetic resonance imaging-based hippocampal volumetry in patients with dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Measurement of temporal regional cerebral perfusion with single-photon emission tomography predicts rate of decline in language function and survival in early Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Systematic Review of the Diagnostic Accuracy of 99mTc-HMPAO-SPECT in Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The primary care of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Adverse effects of reality orientation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Effects of cholinergic drugs and cognitive training on dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Nonpharmacological cognitive interventions in aging and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Behavioral interventions for agitation in older adults with dementia: an evaluative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Disease-modifying therapies for Alzheimer disease: challenges to early intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

NICE judgment: good law risks bad science.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Antipsychotic drug use and mortality in older adults with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The persistence of neuropsychiatric symptoms in dementia: the Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Family caregiving of persons with dementia: prevalence, health effects, and support strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

National estimates of the quantity and cost of informal caregiving for the elderly with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The burden of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Prevalence and impact of caregiving: a detailed comparison between dementia and nondementia caregivers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Supporting family caregivers at the end of life: "they don't know what they don't know".

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Chronic stress associated with spousal caregiving of patients with Alzheimer's dementia is associated with downregulation of B-lymphocyte GH mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Accelerated risk of hypertensive blood pressure recordings among Alzheimer caregivers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Health conditions and service utilization of adults with elder care responsibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Caregiving as a risk factor for mortality: the Caregiver Health Effects Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Caregiving and employment: competing or complementary roles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Gain in the caregiving experience: where are we? What next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The frustrations, gratifications, and well-being of dementia caregivers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

When Home Caregiving Ends: A Longitudinal Study of Outcomes for Caregivers of Relatives with Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Patient and caregiver characteristics and nursing home placement in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Hospitalization rates in nursing home residents with dementia. A pilot study of the impact of a special care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Dimensions of care for dementia sufferers in long-term care institutions: are they related to outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Service inputs and costs of care related to outcomes among cognitively impaired nursing home residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Transient cognitive impairment due to glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Incidence and subtypes of dementia in three elderly populations of central Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Incidence and etiology of dementia in a large elderly Italian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Incidence of dementia: does gender make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Is the dementia rate increasing in Beijing? Prevalence and incidence of dementia 10 years later in an urban elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Incidence of Alzheimer's disease in a rural community in India: the Indo-US study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Prevalence of dementia in the United States: the aging, demographics, and memory study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Prevalence of Alzheimer's disease and other dementing disorders: Assiut-Upper Egypt study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The prevalence of dementia in an urban Turkish population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The prevalence of dementia in the People's Republic of China: a systematic analysis of 1980-2004 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

A review of screening tests for cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The reliability and validity of the Mini-Mental State in a British community survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Comparison of two screening tests in Alzheimer's disease. The correlation and reliability of the Mini-Mental State Examination and the modified Blessed test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Do long tests yield a more accurate diagnosis of dementia than short tests? A comparison of 5 neuropsychological tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Diagnostic utility of letter fluency, category fluency, and fluency difference scores in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

The three-item clock-drawing test: a simplified screening test for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Biomarkers in the diagnosis of Alzheimer's disease: are we ready?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Clearing amyloid through the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Autoantibodies to amyloid-beta and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Identification of the origin of double minutes in normal human cells by laser-based chromosome microdissection approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Relation between smoking and risk of dementia and Alzheimer disease: The Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Behavioral Syndromes in Alzheimer’s Disease: Description and Correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Positive Aspects of Caregiving

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

Clinical and pathological correlates of apolipoprotein E ?4 in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXN008

21 January 2018

Identifiers

DOI

10.1093/EPIREV/MXN008

1 reference

release_2db7jvbdcbe6dmitf2z4nzr42y

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2db7jvbdcbe6dmitf2z4nzr42y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference